NEW YORK, Dec. 30 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. today announced that Ron Bentsur, Vice President of Finance & Investor Relations, has accepted the position as Chief Executive Officer of XTL Biopharmaceuticals, Ltd. Mr. Bentsur will remain as Vice President, Finance and Investor Relations of Keryx until a successor is named.
ABOUT KERYX BIOPHARMACEUTICALS, INC.
Keryx Biopharmaceuticals, Inc. is focused on the acquisition, development and commercialization of novel pharmaceutical products for the treatment of life-threatening diseases, including diabetes and cancer. Keryx’s lead compound under development is KRX-101 (sulodexide), a first-in-class, oral heparinoid compound for the treatment of diabetic nephropathy, a life-threatening kidney disease caused by diabetes. KRX-101 is in a pivotal Phase 3 and Phase 4 clinical program under a Special Protocol Assessment with the Food & Drug Administration. Additionally, Keryx is developing clinical-stage oncology compounds, including KRX-0401, a novel, first-in-class, oral modulator of Akt, a pathway associated with tumor survival and growth, and other important signal transduction pathways. KRX-0401 is currently in Phase 2 clinical development for multiple tumor types. Keryx also has an active in-licensing and acquisition program designed to identify and acquire additional drug candidates. Keryx is headquartered in New York City.
KERYX CONTACT: Ron Bentsur Vice President - Finance & Investor Relations Keryx Biopharmaceuticals, Inc. Tel: 212.531.5965 E-mail: ron@keryx.com
Keryx Biopharmaceuticals, Inc.
CONTACT: Ron Bentsur, Vice President - Finance & Investor Relations ofKeryx Biopharmaceuticals, Inc., +1-212-531-5965, ron@keryx.com
